Aventis net profit up 24 percent to 15 crore
By Nisha Das | 20 Oct 2001
Mumbai: Aventis Pharma has recorded a net profit of Rs 15.2 crore (a growth of 24 per cent) during the third quarter ended 30 September. Its net profit in the corresponding period last year was Rs 12.3 crore.
The company's net sales during the reporting quarter went up by 5.5 per cent to Rs 152 crore from Rs 144.4 crore on a year-on-year basis. The export sales of Rs 28.8 crore showed an excellent growth of 43 per cent with a good recovery in the CIS and expansion in the new markets of Central Asian Republics.
The operating profit registered an increase of 26 per cent from Rs 23.6 crore to Rs 29.7 crore. The operating margin too improved from 16.1 per cent to 19.1 per cent during the same period.
During the period under review, the company launched Arava, a novel treatment for rheumatoid arthritis, from the parent research pipeline. With this, the company has entered into a new therapeutic area with great potential. Strategic brands led by Cardace (61 per cent), Allegra (51 per cent) and Amaryl (48 per cent) showed a strong growth.
The company has also declared an interim dividend of Rs 2.50 per share.
